E
Traws Pharma, Inc.
TRAW
$2.00
$0.2514.29%
E
Sell
8/21/2024Downgrade
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 8/21/2024 due to a large decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.2368 to -$4.8652, operating cash flow declined 122.69% from -$4.42M to -$9.85M, and EBIT declined 12.89% from -$5.21M to -$5.88M.
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 8/21/2024 due to a large decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.2368 to -$4.8652, operating cash flow declined 122.69% from -$4.42M to -$9.85M, and EBIT declined 12.89% from -$5.21M to -$5.88M.
D
Sell
8/16/2024Upgraded
Traws Pharma, Inc. (TRAW) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index and valuation index.
Traws Pharma, Inc. (TRAW) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index and valuation index.
E
Sell
7/31/2024Downgrade
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 7/31/2024 due to a decline in the volatility index, total return index and valuation index.
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 7/31/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
7/15/2024Upgraded
Traws Pharma, Inc. (TRAW) was upgraded to D- from E+ on 7/15/2024 due to an increase in the volatility index and valuation index.
Traws Pharma, Inc. (TRAW) was upgraded to D- from E+ on 7/15/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/17/2024Downgrade
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 6/17/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 2.26 to 1.74.
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D- on 6/17/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 2.26 to 1.74.
D
Sell
2/9/2024Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 2/9/2024 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 2/9/2024 due to an increase in the volatility index.
E
Sell
10/12/2023Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 10/12/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.71 to 3.43.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 10/12/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.71 to 3.43.
D
Sell
5/24/2023Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 5/24/2023 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 5/24/2023 due to an increase in the volatility index.
E
Sell
5/12/2023Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index and growth index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index and growth index.
D
Sell
4/21/2023Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 4/21/2023 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 4/21/2023 due to an increase in the volatility index.
E
Sell
4/6/2023Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 4/6/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 5.81 to 4.82, total revenue declined 1.75% from $57 to $56, and EBIT declined 1.65% from -$5.64M to -$5.73M.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 4/6/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 5.81 to 4.82, total revenue declined 1.75% from $57 to $56, and EBIT declined 1.65% from -$5.64M to -$5.73M.
D
Sell
3/29/2023Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 3/29/2023 due to an increase in the total return index and volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 3/29/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D on 03/14/2023.
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index and growth index. EBIT declined 36.92% from -$4.12M to -$5.64M, earnings per share declined from -$0.1925 to -$0.2581, and the quick ratio declined from 7.21 to 5.81.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index and growth index. EBIT declined 36.92% from -$4.12M to -$5.64M, earnings per share declined from -$0.1925 to -$0.2581, and the quick ratio declined from 7.21 to 5.81.
D
Sell
7/28/2022Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index.
D
Sell
7/13/2022Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index.
D
Sell
6/22/2022Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 6/22/2022 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 6/22/2022 due to an increase in the volatility index.
D
Sell
6/6/2022Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index and total return index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index and total return index.
D
Sell
5/16/2022Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index and volatility index. Total revenue declined 1.75% from $57 to $56.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index and volatility index. Total revenue declined 1.75% from $57 to $56.
D
Sell
11/9/2021Upgraded
Traws Pharma, Inc. (TRAW) was upgraded to D from E+ on 11/09/2021.
Traws Pharma, Inc. (TRAW) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D on 11/08/2021.
Traws Pharma, Inc. (TRAW) was downgraded to E+ from D on 11/08/2021.
D
Sell
12/31/2020Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 12/31/2020 due to an increase in the total return index and volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 12/31/2020 due to an increase in the total return index and volatility index.
D
Sell
12/11/2020Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 12/11/2020 due to a decline in the valuation index and volatility index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 12/11/2020 due to a decline in the valuation index and volatility index.
D
Sell
11/20/2020Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 11/20/2020 due to an increase in the growth index and solvency index. Earnings per share increased from -$0.0436 to -$0.0345, total revenue increased 17.86% from $56 to $66, and EBIT increased 14.51% from -$7.34M to -$6.27M.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 11/20/2020 due to an increase in the growth index and solvency index. Earnings per share increased from -$0.0436 to -$0.0345, total revenue increased 17.86% from $56 to $66, and EBIT increased 14.51% from -$7.34M to -$6.27M.
D
Sell
10/30/2020Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 10/30/2020 due to a decline in the total return index and volatility index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 10/30/2020 due to a decline in the total return index and volatility index.
D
Sell
9/11/2020Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 9/11/2020 due to an increase in the valuation index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 9/11/2020 due to an increase in the valuation index.
D
Sell
8/27/2020Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 8/27/2020 due to a noticeable decline in the efficiency index, growth index and valuation index. Net income declined 45.23% from -$5.09M to -$7.4M, EBIT declined 43.2% from -$5.13M to -$7.34M, and earnings per share declined from -$0.0318 to -$0.0436.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 8/27/2020 due to a noticeable decline in the efficiency index, growth index and valuation index. Net income declined 45.23% from -$5.09M to -$7.4M, EBIT declined 43.2% from -$5.13M to -$7.34M, and earnings per share declined from -$0.0318 to -$0.0436.
D
Sell
3/30/2020Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 3/30/2020 due to an increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.59 to 2.75, and earnings per share increased from -$0.7481 to -$0.1453.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 3/30/2020 due to an increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.59 to 2.75, and earnings per share increased from -$0.7481 to -$0.1453.
D
Sell
11/14/2019Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 11/14/2019 due to a significant decline in the efficiency index, solvency index and total return index. Total capital declined 32.89% from -$4.55M to -$6.04M, the quick ratio declined from 0.87 to 0.59, and net income declined 29.04% from -$3.56M to -$4.6M.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 11/14/2019 due to a significant decline in the efficiency index, solvency index and total return index. Total capital declined 32.89% from -$4.55M to -$6.04M, the quick ratio declined from 0.87 to 0.59, and net income declined 29.04% from -$3.56M to -$4.6M.
D
Sell
5/28/2019Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 5/28/2019 due to a significant increase in the efficiency index, volatility index and total return index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 5/28/2019 due to a significant increase in the efficiency index, volatility index and total return index.
D
Sell
11/21/2018Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 11/21/2018 due to a noticeable decline in the growth index. Total revenue declined 75.26% from $485 to $120, and operating cash flow declined 54.71% from -$4.62M to -$7.15M.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 11/21/2018 due to a noticeable decline in the growth index. Total revenue declined 75.26% from $485 to $120, and operating cash flow declined 54.71% from -$4.62M to -$7.15M.
D
Sell
8/17/2018Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 8/17/2018 due to a noticeable increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.73 to 2.97, earnings per share increased from -$0.3362 to -$0.0734, and operating cash flow increased 16.06% from -$5.51M to -$4.62M.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 8/17/2018 due to a noticeable increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.73 to 2.97, earnings per share increased from -$0.3362 to -$0.0734, and operating cash flow increased 16.06% from -$5.51M to -$4.62M.
D
Sell
5/17/2018Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 5/17/2018 due to a significant decline in the efficiency index, solvency index and total return index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 5/17/2018 due to a significant decline in the efficiency index, solvency index and total return index.
D
Sell
5/30/2017Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/30/2017 due to a significant increase in the efficiency index, total return index and volatility index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 5/30/2017 due to a significant increase in the efficiency index, total return index and volatility index.
E
Sell
11/16/2016Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 11/16/2016 due to a decline in the volatility index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D on 11/16/2016 due to a decline in the volatility index.
D
Sell
8/18/2016Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 8/18/2016 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 52.51% from $1.47M to $2.25M, earnings per share increased from -$2.6505 to -$1.9637, and EBIT increased 14.57% from -$6.32M to -$5.4M.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from E+ on 8/18/2016 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 52.51% from $1.47M to $2.25M, earnings per share increased from -$2.6505 to -$1.9637, and EBIT increased 14.57% from -$6.32M to -$5.4M.
E
Sell
5/12/2016Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 5/12/2016 due to a large decline in the growth index, efficiency index and total return index. EBIT declined 334.19% from $3.21M to -$7.52M, net income declined 326.82% from $3.19M to -$7.24M, and earnings per share declined from $0.1279 to -$0.27.
Onconova Therapeutics, Inc. (ONTX) was downgraded to E+ from D- on 5/12/2016 due to a large decline in the growth index, efficiency index and total return index. EBIT declined 334.19% from $3.21M to -$7.52M, net income declined 326.82% from $3.19M to -$7.24M, and earnings per share declined from $0.1279 to -$0.27.
D
Sell
3/11/2016Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
11/20/2015Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D+ from D on 11/20/2015 due to an increase in the efficiency index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D+ from D on 11/20/2015 due to an increase in the efficiency index.
D
Sell
10/19/2015Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 10/19/2015 due to an increase in the volatility index, total return index and valuation index.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D from D- on 10/19/2015 due to an increase in the volatility index, total return index and valuation index.
D
Sell
8/14/2015Downgrade
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 8/14/2015 due to a decline in the solvency index, valuation index and efficiency index. Total capital declined 63.71% from $12.61M to $4.58M, net income declined 27.45% from -$12.34M to -$8.96M, and the quick ratio declined from 3.13 to 2.55.
Onconova Therapeutics, Inc. (ONTX) was downgraded to D- from D on 8/14/2015 due to a decline in the solvency index, valuation index and efficiency index. Total capital declined 63.71% from $12.61M to $4.58M, net income declined 27.45% from -$12.34M to -$8.96M, and the quick ratio declined from 3.13 to 2.55.
D
Sell
8/1/2014Upgraded
Traws Pharma, Inc. (TRAW) was upgraded to D from D- on 08/01/2014.
Traws Pharma, Inc. (TRAW) was upgraded to D from D- on 08/01/2014.
D
Sell
4/1/2014Upgraded
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 4/1/2014 due to a large increase in the growth index. Total revenue increased 72.94% from $1.12M to $1.93M, and operating cash flow increased 19.21% from -$14.37M to -$17.13M.
Onconova Therapeutics, Inc. (ONTX) was upgraded to D- from E+ on 4/1/2014 due to a large increase in the growth index. Total revenue increased 72.94% from $1.12M to $1.93M, and operating cash flow increased 19.21% from -$14.37M to -$17.13M.
NASDAQ
04/11/2025 3:59PM Eastern
Quotes delayed
